Filtreler
Intrarenal surgery vs percutaneous nephrolithotomy in the management of lower pole stones greater than 2 cm

Koyuncu, H. | Yencilek, F. | Kalkan, M. | Bastug, Y. | Yencilek, E. | Ozdemir, A.T.

Article | 2015 | International Braz J Urol41 ( 2 ) , pp.245 - 251

Purpose: To compare the efficacy of RIRS and PNL in lower pole stones ?2 cm. Materials and and Methods: A total of 109 patients who underwent PNL or RIRS for solitary lower pole stone between April 2009 and December 2012, were retrospectively analyzed. Lower pole stone was diagnosed with CT scan. Stone size was assessed as the longest axis of the stone. All patients were informed about the advantages, disadvantages and probable complications of both PNL and RIRS before the selection of the procedure. Patients decided the surgery type by themselves without being under any influences and written informed consent was obtained from all . . .patients prior to the surgery. Patients were divided into two groups according to the patients' preference of surgery type. Group 1 consisted of 77 patients who underwent PNL and Group 2 consisted of 32 patients treated with RIRS. Stone free statuses, postoperative complications, operative time and hospitalization time were compared in both groups. Results: There was no statistical significance between the two groups in mean age, stone size, stone laterality, mean follow-up periods and mean operative times. In PNL group, stone-free rate was 96.1% at first session and 100% after the additional procedure. In Group 2, stone-free rate was 90.6% at the first procedure and 100% after the additional procedure. The final stone-free rates and operative times were similar in both groups. Conclusions: RIRS should be an effective treatment alternative to PNL in lower pole stones larger than 2 cm, especially in selected patients Daha fazlası Daha az

Investigation of interleukin-1? Polymorphisms in prostate cancer

Yencilek, F. | Yildirim, A. | Yilmaz, S.G. | Altinkilic, E.M. | Dalan, A.B. | Bastug, Y. | İşbir, Turgay

Article | 2015 | Anticancer Research35 ( 11 ) , pp.6057 - 6061

Background: Cytokine-mediated immune and inflammatory responses are considered to play an important role in the pathogenesis of prostate cancer. The present study investigated certain interleukin-1? (IL1?) polymorphisms and their association with prostate cancer. Materials and Methods: Genotyping of the IL1B-31(rs 1143627 G>A) and IL1B-511(rs 16944 A

Change in smoking habits and contribution of physicians to smoking cessation in patients with nonmuscle-invasive bladder cancer

Kalkan, M. | Uzun, H. | Turkan, S. | Sahin, C. | Fatma, F. | Yencilek, F. | Koyuncu, H.

Article | 2015 | European Journal of General Medicine12 ( 2 ) , pp.101 - 103

To assess the impact of a diagnosis of bladder cancer on smoking behavior and to analyze the role of the physician in smoking cessation. Nonmuscle-invasive bladder cancer patients completed a phone survey of their smoking habits. They were asked about smoking behavior before and after the diagnosis of cancer and whether they had been informed by their physician about the relation between smoking and bladder cancer. Two hundred-twelve patients responded to the survey. The mean age was 60.03±6.36 years. Ninety-three of the 135 current smokers (68.9%) were advised to quit smoking, whereas nine of 20 nonsmokers (45%) were not commented . . .about the future risks of smoking. The results showed that 13% of the current smokers and 35% of the current nonsmokers were not warned about the relation of bladder cancer with smoking. Statistical significance was not seen in terms of sex, disease stage, and tumor grade at diagnosis. The relation between smoking and bladder cancer has been well established. However, some patients are not informed to quit smoking by their physicians. © 2015, TIP ARASTIRMALARI DERNEGI. All rights reserved Daha fazlası Daha az

6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms